Rivastigmine Tartrate Capsule
Product Images NDC 62332-065

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 62332-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Rivastigmine 1 5mg 30 Bottle)

Rivastigmine Tartrate Capsules, USP 1.5 mg oral capsules packaging label by Alembic Pharmaceuticals Inc. The label shows 30 capsules per container, NDC 62332-063-30, with storage instructions and manufacturer details. The label includes a barcode and states the product is Rx only.*

FDA Label Image

30 Capsules (Rivastigmine 3mg 30 Bottle)

Rivastigmine Tartrate Capsules USP 3 mg label from Alembic Pharmaceuticals Inc. The label states the dosage strength as 3 mg per capsule and the package count as 30 capsules. It includes storage instructions and manufacturer details for Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA. The label also contains the NDC number 62332-064-30 and a barcode.*

FDA Label Image

30 Capsules (Rivastigmine 4 5mg 30 Bottle)

Rivastigmine Tartrate Capsules, USP 4.5 mg strength, oral dosage form, manufactured by Alembic Pharmaceuticals Inc. The label displays NDC 62332-065-30, indicates a package quantity of 30 capsules, and includes storage instructions and manufacturing details for Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals Inc. in the USA.*

FDA Label Image

30 Capsules (Rivastigmine 6mg 30 Bottle)

Rivastigmine Tartrate Capsules, USP 6 mg oral capsules packaging label showing 30 capsules per bottle. The label includes storage instructions, manufacturer details (Alembic Pharmaceuticals Inc.), and a National Drug Code (NDC) 62332-066-30. It states Rx only and has the Alembic logo in blue.*

FDA Label Image

Figure 1 (Rivastigmine Fig1)

A line graph depicting the mean change from baseline in ADAS-cog rating over 26 weeks of treatment. The vertical axis shows the mean change with SEM, indicating clinical improvement or decline. Three groups are compared: 6-12 mg, 1-4 mg, and placebo, illustrating different trends in cognitive change during treatment weeks.*

FDA Label Image

Figure 2 (Rivastigmine Fig2)

A cumulative percentage of patients graph showing change from baseline in ADAS-cog scores for treatment groups receiving 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline, while the y-axis shows cumulative percentage of patients. The figure compares cognitive changes with annotations at -7 and -4 points and a table summarizing treatment group data versus placebo.*

FDA Label Image

Figure 3 (Rivastigmine Fig3)

A bar chart comparing the percentage of patients across different CIBIC-Plus Rating categories for three groups: Placebo, 1-4 mg, and 6-12 mg. The categories range from Markedly Improved to Markedly Worse, with the highest percentage of patients in the Unchanged category for all groups.*

FDA Label Image

Figure 4 (Rivastigmine Fig4)

A line graph showing mean change from baseline in ADAS-cog rating over 26 weeks during treatment with Rivastigmine Tartrate at doses 6-12 mg, 1-4 mg, and placebo. The 6-12 mg group shows clinical improvement, while 1-4 mg and placebo groups show clinical decline, with error bars indicating SEM.*

FDA Label Image

Figure 5 (Rivastigmine Fig5)

A cumulative percentage plot showing change from baseline in ADAS-cog scores among treatment groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline in points, with markers for 0, 4, and 7 points. The y-axis shows cumulative percentage of patients. A table compares change scores by group, highlighting cognitive changes with higher doses.*

FDA Label Image

Figure 6 (Rivastigmine Fig6)

A bar chart displaying the distribution of patients by CIBIC-Plus rating categories following treatment with rivastigmine tartrate in doses of 1-4 mg and 6-12 mg compared to placebo. The x-axis lists the CIBIC-Plus categories from markedly improved to markedly worse, while the y-axis shows the percentage of patients. Each category has bars representing placebo (black), 1-4 mg dose (white), and 6-12 mg dose (gray).*

FDA Label Image

Figure 8 (Rivastigmine Fig8)

A bar chart showing the distribution of ADCS CGIC ratings comparing Rivastigmine Tartrate and placebo in patients. The x-axis lists categories from Markedly improved to Markedly worse, while the y-axis shows the percentage of patients. Data bars illustrate comparative percentages for each category between the drug and placebo groups.*

FDA Label Image

Figure 7 (Rivastigmine Figure7)

A line graph depicting the mean change from baseline ADAS-cog ratings over 24 weeks during treatment. It compares Rivastigmine Tartrate and placebo groups, showing clinical improvement and decline trends with error bars representing SEM.*

FDA Label Image

Structure (Rivastigmine Structure)

Chemical structure of Rivastigmine Tartrate showing its molecular arrangement with a benzene ring and various attached functional groups, including methyl and carbamate groups, alongside the tartrate component (C4H6O6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.